Опубликована: Дек. 28, 2024
Язык: Английский
Biosensors, Год журнала: 2025, Номер 15(1), С. 50 - 50
Опубликована: Янв. 15, 2025
The detection of low-molecular-weight biomarkers is essential for diagnosing and managing various diseases, including neurodegenerative conditions such as Alzheimer’s disease. A biomarker’s low molecular weight a challenge label-free optical modalities, the phase change they detect directly proportional to mass bound on sensor’s surface. To address this challenge, we used resonant Young’s slit interferometer geometry implemented several innovations, noise matching optimisation fringe spacing, maximise signal-to-noise ratio. As result, achieved limit 2.9 × 10−6 refractive index units (RIU). We validated our capability by demonstrating Aβ-42, 4.5 kDa peptide indicative disease, reached clinically relevant pg/mL regime. This system builds guided mode resonance modality previously showed be compatible with handheld operation using low-cost components. expect development will have far-reaching applications beyond Aβ-42 become workhorse tool across range disease types.
Язык: Английский
Процитировано
1
Clinical Chemistry and Laboratory Medicine (CCLM), Год журнала: 2024, Номер 62(12), С. 2373 - 2387
Опубликована: Сен. 11, 2024
Abstract The ultimate goal of value-based laboratory medicine is maximizing the effectiveness tests in improving patient outcomes, optimizing resources and minimizing unnecessary costs. This approach abandons oversimplified notion test volume cost, favor emphasizing clinical utility quality diagnostic decision-making. Several key elements characterize medicine, which can be summarized some basic concepts, such as organization vitro diagnostics (including appropriateness, integrated diagnostics, networking, remote monitoring, disruptive innovations), translation data into information measurable sustainability, reimbursement, ethics (e.g., empowerment safety, protection, analysis big data, scientific publishing). Education training are also crucial, along with considerations for future profession, will largely influenced by advances automation, technology, artificial intelligence, regulations concerning diagnostics. collective opinion paper, composed summaries from presentations given at two-day European Federation Laboratory Medicine (EFLM) Strategic Conference “A vision to future: medicine” (Padova, Italy; September 23–24, 2024), aims provide a comprehensive overview projecting profession more clinically effective sustainable future.
Язык: Английский
Процитировано
6
Translational Psychiatry, Год журнала: 2024, Номер 14(1)
Опубликована: Июль 9, 2024
Frailty is a common age-related clinical syndrome characterized by decline in the function of multiple organ systems, increased vulnerability to stressors, and huge socio-economic burden. Despite recent research efforts, physiopathological mechanisms underlying frailty remain elusive biomarkers able predate its occurrence early stages are still lacking. Beyond physical component, cognitive represents critical domain associated with higher risk adverse health outcomes. We measured High-Performance Liquid Chromatography (HPLC) pool serum amino acids including L-glutamate, L-aspartate, glycine, D-serine, as well their precursors L-glutamine, L-asparagine, L-serine cohort elderly subjects encompassing entire continuum from fitness frailty. These known orchestrate excitatory inhibitory neurotransmission, turn, play key role intermediates energy homeostasis liver, kidney, muscle, immune system metabolism. To comprehensively assess frailty, we employed both Edmonton Frail Scale (EFS), practical tool capture multidimensionality phenotype, measure function. found that D-serine D-/Total serine ratio were independent predictors EFS but not Furthermore, levels glycine/L-serine worse cognition depressive symptoms frail group. findings suggest changes peripheral glycine enantiomers may represent novel biochemical correlate
Язык: Английский
Процитировано
5
International Journal of Molecular Sciences, Год журнала: 2024, Номер 25(20), С. 10911 - 10911
Опубликована: Окт. 10, 2024
Alzheimer’s disease (AD), the most prevalent form of dementia, is expected to rise dramatically in incidence due global population aging. Traditional diagnostic approaches, such as cerebrospinal fluid analysis and positron emission tomography, are expensive invasive, limiting their routine clinical use. Recent advances blood-based biomarkers, including amyloid-beta, phosphorylated tau, neurofilament light, offer promising non-invasive alternatives for early AD detection monitoring. This review synthesizes current research on these highlighting potential track pathology enhance accuracy. Furthermore, this uniquely integrates recent findings protein-protein interaction networks microRNA pathways, exploring novel combinations proteomic, genomic, epigenomic biomarkers that provide new insights into AD’s molecular mechanisms. Additionally, we discuss integration with advanced neuroimaging techniques, emphasizing revolutionize diagnostics. Although large-scale validation still needed, represent a critical advancement toward more accessible, cost-effective, tools AD.
Язык: Английский
Процитировано
4
The Journal of Applied Laboratory Medicine, Год журнала: 2025, Номер unknown
Опубликована: Янв. 21, 2025
Abstract Background Blood-based biomarkers, especially P-tau217, have been gaining interest as diagnostic tools to measure Alzheimer disease (AD) pathology. Methods We developed a plasma P-tau217 chemiluminescent immunoassay using 4G10E2 and IBA493 antibodies, synthetic tau peptide calibrator, the Quanterix SP-X imager. Analytical validation performed in College of American Pathologists-accredited CLIA laboratory involved multiple kit lots, operators, timepoints, imagers. Florbetapir positron emission tomography was used quantify amyloid for clinical validation. Results Precision across 80 runs ≤20% CV 23 patient-derived samples ranging from 0.09 U/mL 3.35 U/mL. No significant lot-to-lot differences were observed. There no interference purified (2N4R) or lipemia, but hemolysis greater than 2 + not acceptable. Functional analytical sensitivity (lower limit quantitation) 0.08 Linearity studies support use standard 1:2 dilution. Samples demonstrated stability at 7 freeze/thaw cycles, with room temperature refrigerated established up 72 hours. The final measurement range 2.81 calibration curve maintained raw signal intensity 80% 120% relative error back-fitted concentration log-log power regression. Initial assessment 1091 individuals screened TRAILBLAZER-ALZ an area under 91.6% (95% CI 0.90–0.94) brain comparator. Positive negative predictive value >90% >85%, respectively. Conclusions Through validation, this assay robust performance instruments could be tool diagnosing AD.
Язык: Английский
Процитировано
0
The Journal of Prevention of Alzheimer s Disease, Год журнала: 2025, Номер 12(2), С. 100027 - 100027
Опубликована: Янв. 23, 2025
Язык: Английский
Процитировано
0
Brain Research, Год журнала: 2025, Номер unknown, С. 149478 - 149478
Опубликована: Янв. 1, 2025
Язык: Английский
Процитировано
0
International Journal of Molecular Sciences, Год журнала: 2025, Номер 26(5), С. 1935 - 1935
Опубликована: Фев. 24, 2025
The role of amyloid beta peptide (Aβ) in memory regulation has been a subject substantial interest and debate neuroscience, because both physiological clinical issues. Understanding the dual nature Aβ is crucial for developing effective treatments Alzheimer's disease (AD). Moreover, accurate detection quantification methods isoforms have tested diagnostic purposes therapeutic interventions. This review provides insight into current knowledge about vivo vitro by fluid tests brain imaging (PET), which allow preclinical recognition disease. Currently, priority development new therapies given to potential changes progression In light increasing amounts data, this was focused on employment
Язык: Английский
Процитировано
0
Cureus, Год журнала: 2025, Номер unknown
Опубликована: Март 1, 2025
Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by cognitive decline and neuropathological features such as amyloid-β (Aβ) plaques phosphorylated tau (p-Tau) tangles. Blood-based biomarkers of Aβ p-Tau have emerged promising tools for early diagnosis, monitoring, risk stratification AD. This systematic review evaluates current evidence on the diagnostic utility blood in followed Preferred Reporting Items Systematic Reviews Meta-Analyses (PRISMA) guidelines. A comprehensive literature search was conducted across PubMed, Scopus, Web Science studies published between 2011 2024. synthesizes findings from 33 peer-reviewed to evaluate prognostic these biomarkers. Results demonstrate that levels strongly correlate with cerebrospinal fluid (CSF) neuroimaging measures AD pathology. Among analyzed, (including p-Tau181 p-Tau217) consistently exhibited superior accuracy, particularly distinguishing mild impairment (MCI) cognitively normal individuals. The combination further improved precision, supporting their complementary roles pathology detection. Despite findings, significant heterogeneity among underscores need assay standardization, validation diverse populations, longitudinal research establish clinical utility. study concludes blood-based represent advance diagnostics, offering non-invasive, cost-effective, scalable solutions detection therapeutic monitoring.
Язык: Английский
Процитировано
0
Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring, Год журнала: 2025, Номер 17(1)
Опубликована: Янв. 1, 2025
Язык: Английский
Процитировано
0